Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. (Q51560648)

7 April 2018

title

Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. (English)

1 reference

7 April 2018

author name string

Gutteridge DH

1

1 reference

7 April 2018

Ward LC

2

1 reference

7 April 2018

Stewart GO

3

1 reference

7 April 2018

Retallack RW

4

1 reference

7 April 2018

Will RK

5

1 reference

7 April 2018

Prince RL

6

1 reference

7 April 2018

Criddle A

7

1 reference

7 April 2018

Bhagat CI

8

1 reference

7 April 2018

Stuckey BG

9

1 reference

7 April 2018

Price RI

10

1 reference

7 April 2018

Kent GN

11

1 reference

7 April 2018

Faulkner DL

12

1 reference

7 April 2018

Geelhoed E

13

1 reference

7 April 2018

Gan SK

14

1 reference

7 April 2018

Vasikaran S

15

1 reference

7 April 2018

publication date

1 October 1999

1 reference

7 April 2018

Journal of Bone and Mineral Research

published in

1 reference

7 April 2018

volume

14 Suppl 2

1 reference

7 April 2018

page(s)

79-84

1 reference

7 April 2018

Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140216

Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140216

Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140216

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140216

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140216

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140216

Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140216

Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140216

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140216

21 January 2018

Identifiers

DOI

10.1002/JBMR.5650140216

1 reference

7 April 2018

PubMed ID

10510219

1 reference

7 April 2018